Clinical trials: Substance-Related Disorder
Cocaine Addiction, Cocaine Dependence
Vigabatrin for the Treatment of Cocaine Dependency
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's…
- Trial name
- NCT01281202
- Testing
- Vigabatrin
- Where
- 13 sites in United States
- Volunteers
- 207 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Cocaine Use Disorder, Cocaine Dependence
TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function.
- Trial name
- NCT04994821
- Testing
- transcranial direct current stimulator (tDCS), Cognitive Reappraisal
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Soterix Medical
Alcohol Use Disorder
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare
This is an exempt, retrospective study of a limited set of information obtained from patients' medical records at 10 to 12 substance abuse treatment programs combined with alcohol breath analyzer results during up to 3 years of…
- Trial name
- NCT02544581
- Testing
- Soberlink combined with aftercare services
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- SoberLink, LLC
Opioid-Related Disorders, Opiate Addiction
Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication
The purpose is to validate the PRISM-5-Op as a measurement of prescription opioid substance use disorder.
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02660619
- Testing
- Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)
- Volunteers
- 606 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Alcohol Dependence
ALK33-001: A Study of RDC-0313 Administered to Healthy Adults
The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of RDC-0313 following oral administration.
- Trial name
- NCT00800319
- Testing
- RDC-0313
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Alcohol Use Disorder
Contingency Management for Alcohol Use Disorder
Randomized pilot study of a device (smartphone app) that poses non-significant risk to participants and is exempt from Investigational Device Exemption regulations [21 Code of Federal Regulations 812.2(c)
- Trial name
- NCT03701204
- Testing
- DynamiCare Rewards
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- DynamiCare Health
Marijuana Abuse
Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects
Cannabis use is increasing and will only further escalate with legalization of recreational and medical cannabis use in western countries , with a prevalence greater than 30 % in the US and most European countries for individuals…
- Trial name
- NCT05554926
- Testing
- AEF0117
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Aelis Farma
Patient Engagement, COVID-19
Collaborative Open Research Initiative Study (CORIS-1)
The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education.
- Conditions
- Patient Engagement, COVID-19, Preventable Disease, Vaccine, Burnout, Professional
- Trial name
- CORIS-1 (NCT06357650)
- Testing
- No intervention. This is an observational study
- Volunteers
- 15,000 people
- Sponsor
- Chisquares Incorporated
Opioid-use Disorder
Single Ascending Dose Study of ALA-1000
An open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of ALA-1000 in opioid-dependent subjects.
- Trial name
- NCT04122755
- Testing
- ALA-1000, buprenorphine sublingual film
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Alar Pharmaceuticals Inc.
Opioid Overdose
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.
- Trial name
- NCT07543276
- Testing
- Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Knoa Pharma LLC
Substance Use Disorders, Methamphetamine Abuse
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Trial name
- NCT06316973
- Testing
- CS-1103, Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.
Alcohol Use Disorder, Alcohol Abuse
tAN for Substance Use Disorder
The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse, Substance Use Disorders, Substance Use Disorders Alcohol Use Withdrawal State
- Trial name
- NCT07281261
- Testing
- Sparrow Ascent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Alcohol Use Disorder
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
This study is aimed at examining whether GET73 modulates the indices of central glutamate and γ-aminobutyric acid (GABA) levels in recently abstinent subjects that meet Alcohol Use Disorder (AUD) criteria, as measured by proton…
- Trial name
- NCT03418623
- Testing
- GET73
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Drug Abuse
A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users
The purpose of this study is to assess the relative abuse potential of the hydrocodone bitartrate extended-release tablet compared to immediate-release hydrocodone bitartrate.
- Trial name
- NCT01596673
- Testing
- 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
- Where
- 2 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cephalon
Prescription Drug Abuse (Not Dependent), Substance Use
Preventing Prescription Drug Abuse in Middle School Students
This project is designed to test a primary prevention approach to the problem of prescription drug misuse and abuse (PDA) among middle school students.
- Conditions
- Prescription Drug Abuse (Not Dependent), Substance Use, Substance Abuse
- Trial name
- MSPDA (NCT03129334)
- Testing
- LST Middle School Online
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Vaping, E Cig Use
A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach
The goal of this randomized controlled trial is to evaluate a psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription…
- Conditions
- Vaping, E Cig Use, Prescription Drug Misuse
- Trial name
- NCT07162155
- Testing
- School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Healthy Volunteer, Opioid-use Disorder
Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder
The primary objectives for the study are: Part I and Part II: Assess safety and tolerability of repeated doses of INDV-2000 in healthy volunteers.
- Trial name
- NCT04976855
- Testing
- INDV-2000, SUBOXONE® sublingual film
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Opioid Withdrawal, Opioid Use Disorder
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.
- Trial name
- NCT06487533
- Testing
- EmbracePlus Smartwatch, Corti Sensor
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Smoking, Tobacco Use Disorder
QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions
QuitAdvisorMD: A point-of-care tool for brief smoking cessation interventions Under a Phase II SBIR grant supported by NIH/NIDA, we are developing QUITAdvisorMD: a point-of-care, patient-centered resource for counseling patients…
- Trial name
- NCT01065493
- Testing
- QuitAdvisorMD Software Algorithm, Standard Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Silverchair Science & Communications, LLC
Alcohol Use Disorder, Post Traumatic Stress Disorder
CCTAP: Cognitive Control Training for Treatment of AUD-PTSD
The primary objective of this study is to evaluate the feasibility of the revised brain training program with individuals diagnosed with Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT03200028
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Posit Science Corporation